SAN FRANCISCO, CA — May 26, 2026 — Omios
Biologics today announced the launch of the Omios Discovery Engine (ODE), a
computational platform designed to identify novel therapeutic targets by
mapping the evolutionary interactions between viruses and human biology. The
company is actively scaling its computational infrastructure and expanding its
therapeutic pipeline. ODE analyzes human-virus interactions to
uncover disease vulnerabilities and translate them into actionable therapeutic
strategies. The platform has already generated three biomarker-guided therapies
for aggressive solid tumors and is advancing toward clinical development with a
major U.S. cancer center. Despite major advances in computational
biology, many therapeutic programs continue to fail due to poor target
selection and a limited understanding of disease mechanisms. Omios developed
ODE to address this challenge by leveraging viral evolutionary biology as a
therapeutic discovery framework. “Viruses have spent hundreds of thousands
of years evolving mechanisms to manipulate human biology,” said Aldo Pourchet,
CEO of Omios Biologics. “We built ODE to systematically identify and harness
these mechanisms for therapeutic discovery. By combining viral biology with
large-scale computational analysis, we uncover highly relevant disease targets
and develop safer and better-performing therapeutic strategies.” Omios recently received the Jury Prize at
the 2026 competition organized by the French American Chamber of Commerce,
recognizing the company’s scientific and entrepreneurial momentum. Building on
its oncology programs, Omios is now expanding the ODE platform into autoimmune,
metabolic, and neurodegenerative diseases. “We look at how viruses hack human cells
and mine this for therapies,” said Anand Pai, CTO of Omios Biologics. “ODE
provides a computational framework for identifying viral mechanisms that
evolved to modulate critical human pathways. This approach enables us to
uncover biologically relevant and potentially druggable targets that may remain
inaccessible through traditional discovery methods.” “Since 2023, Omios has been focused on
the development of our next-generation, systemically delivered,
biomarker-guided oncolytic virus platform,” said Bruno Larida, CBO of Omios.
“We are now entering our next expansion phase with ODE, supported once again by
our world-class team of virologists and drug developers. This platform creates
significant new opportunities within the biopharma industry for pipeline
expansion and early revenue generation.”
Founded in 2023, Omios Biologics is a
California-based computational biotechnology company developing a novel
therapeutic discovery platform. The company utilizes the Omios Discovery Engine
(ODE) to map disease vulnerabilities against the viral interactome and identify
therapeutically actionable targets.
Contact: bruno@omiosbio.com
Bruno Larida
Chief Business Officer
omiosbio.com
